Tumor lysate-loaded biodegradable microparticles as cancer vaccines

Vijaya B Joshi; Sean M Geary; Brett P Gross; Amaraporn Wongrakpanich; Lyse A Norian; Aliasger K Salem

doi:10.1586/14760584.2014.851606

Back

Tumor lysate-loaded biodegradable microparticles as cancer vaccines

Journal article

Peer reviewed

Tumor lysate-loaded biodegradable microparticles as cancer vaccines

Vijaya B Joshi, Sean M Geary, Brett P Gross, Amaraporn Wongrakpanich, Lyse A Norian and Aliasger K Salem

Expert Review of Vaccines, Vol.13(1), pp.9-15

01/01/2014

DOI: 10.1586/14760584.2014.851606

PMCID: PMC3968791

PMID: 24219096

Files and links (1)

url

http://doi.org/10.1586/14760584.2014.851606View

Open Access

Abstract

Cancer vaccines that use tumor lysate (TL) as a source of tumor-associated antigens (TAAs) have significant potential for generating therapeutic anti-tumor immune responses. Vaccines encompassing TL bypass the limitations of single antigen vaccines by simultaneously stimulating immunity against multiple TAAs, thereby broadening the repertoire of TAA-specific T-cell clones available for activation. Administration of TL in particulate form, such as when encapsulated in biodegradable microparticles, increases its immunostimulatory capacity and produces more robust immune responses than when TL is given in soluble form. These effects can be further enhanced by co-administering TL with adjuvants. A number of recent studies using polymeric microparticle delivery of TL, with or without adjuvants, have produced promising results in preclinical studies. In this review, we will discuss current experimental approaches involving TL being pursued in the oncoimmunology field, and comment on strategies such as combining specific chemotherapeutic agents with TL microparticle delivery that may eventually lead to improved survival outcomes for cancer patients.

tumor lysate

microparticles

vaccine

cancer

biodegradable polymers

Details

Title: Subtitle: Tumor lysate-loaded biodegradable microparticles as cancer vaccines
Creators: Vijaya B Joshi - Division of Pharmaceutics and Translational Therapeutics
Sean M Geary - Division of Pharmaceutics and Translational Therapeutics
Brett P Gross - Interdisciplinary Graduate Program in Immunology, University of Iowa, Carver College of Medicine
Amaraporn Wongrakpanich - Division of Pharmaceutics and Translational Therapeutics
Lyse A Norian - Department of Urology, Carver College of Medicine, University of Iowa
Aliasger K Salem - Division of Pharmaceutics and Translational Therapeutics
Resource Type: Journal article
Publication Details: Expert Review of Vaccines, Vol.13(1), pp.9-15
DOI: 10.1586/14760584.2014.851606
PMID: 24219096
PMCID: PMC3968791
NLM abbreviation: Expert Rev Vaccines
ISSN: 1476-0584
eISSN: 1744-8395
Publisher: Taylor & Francis
Language: English
Date published: 01/01/2014
Academic Unit: Roy J. Carver Department of Biomedical Engineering; Pharmaceutical Sciences and Experimental Therapeutics; Craniofacial Anomalies Research Center; Dental Research; Chemical and Biochemical Engineering
Record Identifier: 9983985947802771

Metrics

14 Record Views

35 Times Cited - Web of Science